Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
View: Text | PDF
Research Article Angiogenesis

VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss

  • Text
  • PDF
Abstract

Millions of people are affected by hearing loss. Hearing loss is frequently caused by noise or aging and often associated with loss of pericytes. Pericytes populate the small vessels in the adult cochlea. However, their role in different types of hearing loss is largely unknown. Using an inducible and conditional pericyte depletion mouse model and noise-exposed mouse model, we show that loss of pericytes leads to marked changes in vascular structure, in turn leading to vascular degeneration and hearing loss. In vitro, using advanced tissue explants from pericyte fluorescence reporter models combined with exogenous donor pericytes, we show that pericytes, signaled by VEGF isoform A165 (VEGFA165), vigorously drive new vessel growth in both adult and neonatal mouse inner ear tissue. In vivo, the delivery of an adeno-associated virus serotype 1–mediated (AAV1–mediated) VEGFA165 viral vector to pericyte-depleted or noise-exposed animals prevented and regenerated lost pericytes, improved blood supply, and attenuated hearing loss. These studies provide the first clear-cut evidence that pericytes are critical for vascular regeneration, vascular stability, and hearing in adults. The restoration of vascular function in the damaged cochlea, including in noise-exposed animals, suggests that VEGFA165 gene therapy could be a new strategy for ameliorating vascular associated hearing disorders.

Authors

Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi

×

Figure 3

Pericytes, signaled by VEGFA165, lead cochlear angiogenesis in adult and neonatal mouse cochleae in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Pericytes, signaled by VEGFA165, lead cochlear angiogenesis in adult and...
(A) Confocal image of the stria from an NG2+DsRed mouse (n = 4) shows pericytes situated on microvessels labeled with an antibody for glucose transporter I (Glut, green). (B) Strial explant from an NG2+DsRed mouse cochlea labeled with Phalloidin and DAPI on day 5 after VEGFA165 treatment. A high-magnification image (inset in B) highlights how NG2-derived pericytes lead new vessel growth (n = 4). (C) An example of sprouting angiogenesis on day 5 from the control group. (D) Pericyte depletion with APB5 treatment impairs angiogenesis. (E) Quantitation of branch number in control and APB5-treated groups shows significant differences (n = 5 for each group, **P < 0.01, and ****P < 0.001 by 1-way ANOVA). (F) Pericytes encoded with pmOrange2-N1. (G) An explant cografted with fluorescence-labeled exogenous pericytes shows some pericytes convert to tip cells (red arrows) and some invest on sprouting branches (white arrows) on day 5 after treatment with VEGFA165. (H) A high-magnification image from an inset in G shows 2 exogenous pericytes with long filopodia situated on the distal end of sprouts. (Background color of inset in H was changed using Photoshop for better visualization of tip cells originating from donor pericytes.) (I and J) Confocal images show sprouting angiogenesis on day 4 in control and pericyte-depleted groups from neonatal mice. Zoomed-in images from insets in I and J better show NG2-derived pericyte-led branch formation in the control (I) and pericyte-depleted groups (J). (M and N) Reconstructions in 3D of confocal images from control and pericyte-depleted groups show less branch formation when pericytes are depleted. (O) Quantitative analysis of branch number in the 2 groups for each day (n = 6 for each group, **P < 0.01, and ****P < 0.0001 by Student’s t test) or (P) on day 4 (n = 6, ****P < 0.0001 by Student’s t test). Scale bars: 10 μm (A, B inset), 100 μm (B–D, F, G, I–N), 50 μm (H).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts